0000805928-22-000033.txt : 20220318 0000805928-22-000033.hdr.sgml : 20220318 20220318161010 ACCESSION NUMBER: 0000805928-22-000033 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220316 FILED AS OF DATE: 20220318 DATE AS OF CHANGE: 20220318 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sandberg Eric CENTRAL INDEX KEY: 0001764446 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36046 FILM NUMBER: 22752623 MAIL ADDRESS: STREET 1: C/O AXOGEN, INC. STREET 2: 13631 PROGRESS BLVD., SUITE 400 CITY: ALACHUA STATE: FL ZIP: 32615 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Axogen, Inc. CENTRAL INDEX KEY: 0000805928 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 411301878 STATE OF INCORPORATION: MN FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 13631 PROGRESS BLVD. STREET 2: SUITE 400 CITY: ALACHUA STATE: FL ZIP: 32615 BUSINESS PHONE: (386) 462-6817 MAIL ADDRESS: STREET 1: 13631 PROGRESS BLVD. STREET 2: SUITE 400 CITY: ALACHUA STATE: FL ZIP: 32615 FORMER COMPANY: FORMER CONFORMED NAME: AxoGen, Inc. DATE OF NAME CHANGE: 20111004 FORMER COMPANY: FORMER CONFORMED NAME: LECTEC CORP /MN/ DATE OF NAME CHANGE: 19920703 4 1 wf-form4_164763418939739.xml FORM 4 X0306 4 2022-03-16 0 0000805928 Axogen, Inc. AXGN 0001764446 Sandberg Eric 13631 PROGRESS BLVD SUITE 400 ALACHUA FL 32615 0 1 0 0 Chief Commercial Officer Common Stock 2022-03-16 4 M 0 6000 0 A 14310 D Common Stock 2022-03-16 4 F 0 1512 7.97 D 12798 D Restricted Stock Units 2022-03-16 4 M 0 6000 0 D Common Stock 6000.0 6000 D Restricted Stock Units 2022-03-16 4 A 0 62910 0 A Common Stock 62910.0 62910 D Employee Stock Option (right to purchase) 10.25 2022-03-16 4 A 0 60576 0 A 2032-03-16 Common Stock 60576.0 60576 D This reflects the number of restricted stock units that became vested as of March 16, 2022. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. The exercise price of $10.25 represents a 25% premium over the fair market value of Axogen common stock on the date of the grant. All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2026 (4 years from the option grant date) based upon a vesting schedule whereby 25% of the aggregate shares vest on March 16, 2023 and on each anniversary thereafter. /s/ Eric Sandberg 2022-03-18